Enanta Pharmaceuticals (ENTA) News Today $5.10 +0.17 (+3.45%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$5.11 +0.01 (+0.20%) As of 04/17/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Trexquant Investment LP Acquires 67,040 Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)Trexquant Investment LP boosted its stake in shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Free Report) by 97.3% during the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 135,954 shares of the biotechnology company's stock after buying an additional 67,040April 14, 2025 | marketbeat.comPrudential Financial Inc. Lowers Stake in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)Prudential Financial Inc. trimmed its stake in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Free Report) by 61.6% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 60,364 shares of the biotechnology company's stocApril 13, 2025 | marketbeat.comEnanta Pharmaceuticals Announces Respiratory Syncytial Virus Data Presentation at ESCMID Global 2025April 8, 2025 | businesswire.comAnalysts Set Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) PT at $17.25April 8, 2025 | americanbankingnews.comEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Receives Average Recommendation of "Moderate Buy" from BrokeragesShares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Get Free Report) have received a consensus rating of "Moderate Buy" from the five ratings firms that are currently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, three have asApril 6, 2025 | marketbeat.comEnanta Pharmaceuticals at H.C. Wainwright: Strategic Shift to ImmunologyMarch 29, 2025 | investing.comEnanta Pharmaceuticals (NASDAQ:ENTA) Stock Price Passes Below Two Hundred Day Moving Average - Here's What HappenedEnanta Pharmaceuticals (NASDAQ:ENTA) Shares Pass Below Two Hundred Day Moving Average - Here's What HappenedMarch 26, 2025 | marketbeat.comShort Interest in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Decreases By 27.2%Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Get Free Report) was the recipient of a large decline in short interest in February. As of February 28th, there was short interest totalling 2,600,000 shares, a decline of 27.2% from the February 13th total of 3,570,000 shares. Based on an average daily volume of 562,300 shares, the days-to-cover ratio is currently 4.6 days. Approximately 13.1% of the shares of the company are short sold.March 17, 2025 | marketbeat.comEnanta Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual ConferenceMarch 17, 2025 | businesswire.comEnanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus Program at the 13th International RSV SymposiumMarch 12, 2025 | finance.yahoo.comEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Given Average Recommendation of "Moderate Buy" by BrokeragesEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Get Free Report) has been assigned an average rating of "Moderate Buy" from the five ratings firms that are currently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, three have given a buy raMarch 11, 2025 | marketbeat.comEnanta Pharmaceuticals (NASDAQ:ENTA) Stock Crosses Below 200 Day Moving Average - Should You Sell?Enanta Pharmaceuticals (NASDAQ:ENTA) Shares Cross Below Two Hundred Day Moving Average - What's Next?March 7, 2025 | marketbeat.comEnanta Pharmaceuticals (NASDAQ:ENTA) Share Price Passes Below Two Hundred Day Moving Average - Time to Sell?Enanta Pharmaceuticals (NASDAQ:ENTA) Share Price Crosses Below Two Hundred Day Moving Average - Time to Sell?February 28, 2025 | marketbeat.comEnanta Pharmaceuticals (NASDAQ:ENTA) Upgraded to "Hold" at StockNews.comStockNews.com raised shares of Enanta Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Wednesday.February 19, 2025 | marketbeat.comEnanta Pharmaceuticals' SWOT analysis: RSV and immunology drive stock outlookFebruary 17, 2025 | msn.comWith Enanta Pharmaceuticals Up 46%, Insider Buyers Count Their ReturnsFebruary 15, 2025 | finance.yahoo.comPresident of Enanta Pharmaceuticals Picks Up 5.9% More StockFebruary 15, 2025 | finance.yahoo.comEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Given Average Rating of "Moderate Buy" by AnalystsEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Get Free Report) has been given a consensus rating of "Moderate Buy" by the five ratings firms that are currently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, three have given a buy recommendaFebruary 14, 2025 | marketbeat.comEnanta Pharmaceuticals CEO Luly Jay R. buys $256,050 in common stockFebruary 13, 2025 | msn.comEnanta Pharmaceuticals (ENTA) Receives a Buy from Evercore ISIFebruary 13, 2025 | markets.businessinsider.comHC Wainwright Issues Pessimistic Estimate for ENTA EarningsEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Free Report) - Equities researchers at HC Wainwright decreased their Q2 2025 earnings per share (EPS) estimates for shares of Enanta Pharmaceuticals in a research note issued to investors on Tuesday, February 11th. HC Wainwright analyst E. Arce now antiFebruary 13, 2025 | marketbeat.comEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) CEO Buys $256,050.00 in StockFebruary 13, 2025 | insidertrades.comJay R. Luly Purchases 45,000 Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) StockEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Get Free Report) CEO Jay R. Luly bought 45,000 shares of the firm's stock in a transaction dated Wednesday, February 12th. The stock was acquired at an average cost of $5.69 per share, with a total value of $256,050.00. Following the transaction, the chief executive officer now owns 846,638 shares of the company's stock, valued at $4,817,370.22. This trade represents a 5.61 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink.February 12, 2025 | marketbeat.comEnanta Pharmaceuticals (NASDAQ:ENTA) Rating Lowered to Sell at StockNews.comStockNews.com downgraded Enanta Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Tuesday.February 11, 2025 | marketbeat.comJMP Securities Reaffirms "Market Outperform" Rating for Enanta Pharmaceuticals (NASDAQ:ENTA)JMP Securities restated a "market outperform" rating and issued a $21.00 price target on shares of Enanta Pharmaceuticals in a research note on Tuesday.February 11, 2025 | marketbeat.comEnanta reports Q1 EPS ($1.05), consensus ($1.35)February 11, 2025 | markets.businessinsider.comJMP Securities maintains Enanta stock with $21 targetFebruary 11, 2025 | msn.comHC Wainwright maintains $18 target on Enanta shares, affirms BuyFebruary 11, 2025 | msn.comHC Wainwright Reiterates Buy Rating for Enanta Pharmaceuticals (NASDAQ:ENTA)HC Wainwright reiterated a "buy" rating and issued a $18.00 price objective on shares of Enanta Pharmaceuticals in a research note on Tuesday.February 11, 2025 | marketbeat.comEnanta Pharmaceuticals (NASDAQ:ENTA) Posts Quarterly Earnings Results, Beats Expectations By $0.11 EPSEnanta Pharmaceuticals (NASDAQ:ENTA - Get Free Report) announced its quarterly earnings results on Monday. The biotechnology company reported ($1.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.16) by $0.11. Enanta Pharmaceuticals had a negative return on equity of 73.02% and a negative net margin of 171.57%.February 10, 2025 | marketbeat.comEnanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2024February 10, 2025 | businesswire.comEnanta Pharmaceuticals (ENTA) Expected to Announce Quarterly Earnings on WednesdayEnanta Pharmaceuticals (NASDAQ:ENTA) will be releasing earnings before the market opens on Wednesday, February 5, Financial Modeling Prep reports.January 29, 2025 | marketbeat.comAssenagon Asset Management S.A. Raises Stock Holdings in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)Assenagon Asset Management S.A. lifted its stake in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Free Report) by 34.1% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 192,856 shares of the biotechnology company's stock aftJanuary 25, 2025 | marketbeat.comJPMorgan Chase & Co. Increases Stock Position in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)JPMorgan Chase & Co. grew its stake in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Free Report) by 53.7% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 243,628 shares of the biotechnolJanuary 21, 2025 | marketbeat.comEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Given Consensus Rating of "Moderate Buy" by BrokeragesShares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the five research firms that are currently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendatJanuary 20, 2025 | marketbeat.comEnanta Pharmaceuticals (ENTA) Receives a Hold from Leerink PartnersJanuary 18, 2025 | markets.businessinsider.comEnanta Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 8, 2025 | uk.finance.yahoo.comQ1 Earnings Estimate for ENTA Issued By HC WainwrightEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Free Report) - Equities researchers at HC Wainwright issued their Q1 2025 earnings estimates for Enanta Pharmaceuticals in a note issued to investors on Tuesday, December 24th. HC Wainwright analyst E. Arce anticipates that the biotechnology company wilDecember 27, 2024 | marketbeat.comEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Given Consensus Recommendation of "Moderate Buy" by AnalystsEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the five ratings firms that are covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell rating, three have given a buy rating and onDecember 26, 2024 | marketbeat.comEnanta to appeal ruling related to ‘953 patent infringement lawsuitDecember 25, 2024 | markets.businessinsider.comEquities Analysts Set Expectations for ENTA FY2029 EarningsEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Free Report) - Equities researchers at HC Wainwright issued their FY2029 earnings per share (EPS) estimates for Enanta Pharmaceuticals in a research report issued on Tuesday, December 24th. HC Wainwright analyst E. Arce expects that the biotechnology coDecember 25, 2024 | marketbeat.comEnanta Pharmaceuticals to Appeal Ruling Related to ‘953 Patent Infringement LawsuitDecember 25, 2024 | uk.finance.yahoo.comEnanta Pharma Stock: A Deep Dive Into Analyst Perspectives (6 Ratings)December 25, 2024 | benzinga.comEnanta Plans To Appeal Court Ruling Related To 953 Patent Infringement LawsuitDecember 25, 2024 | markets.businessinsider.comPromising Virology Outcomes Boost Buy Rating for Enanta Pharmaceuticals Despite Symptom Assessment ConcernsDecember 25, 2024 | markets.businessinsider.comHC Wainwright Has Lowered Expectations for Enanta Pharmaceuticals (NASDAQ:ENTA) Stock PriceHC Wainwright dropped their target price on Enanta Pharmaceuticals from $27.00 to $18.00 and set a "buy" rating on the stock in a report on Tuesday.December 24, 2024 | marketbeat.comEnanta Pharmaceuticals: Undervalued Potential Beyond Hepatitis C – Buy Recommendation by Roy BuchananDecember 14, 2024 | markets.businessinsider.comEvercore ISI Reaffirms Their Buy Rating on Enanta Pharmaceuticals (ENTA)December 12, 2024 | markets.businessinsider.comEquities Analysts Set Expectations for ENTA FY2025 EarningsEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Free Report) - Equities research analysts at Leerink Partnrs lifted their FY2025 earnings estimates for Enanta Pharmaceuticals in a research note issued on Monday, December 9th. Leerink Partnrs analyst R. Ruiz now forecasts that the biotechnology companDecember 12, 2024 | marketbeat.comEnanta Pharmaceuticals (ENTA) Gets a Hold from OppenheimerDecember 11, 2024 | markets.businessinsider.com Get Enanta Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ENTA and its competitors with MarketBeat's FREE daily newsletter. Email Address ENTA Media Mentions By Week ENTA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ENTA News Sentiment▼0.810.49▲Average Medical News Sentiment ENTA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ENTA Articles This Week▼22▲ENTA Articles Average Week Get Enanta Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ENTA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies MNMD News Today PGEN News Today STOK News Today SANA News Today UPB News Today PRTC News Today SION News Today RVNC News Today ABVX News Today ZVRA News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ENTA) was last updated on 4/18/2025 by MarketBeat.com Staff From Our PartnersClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored100-year-old investment secret predicts what?!A 100-year-old indicator has quietly predicted nearly every major market meltdown — including the Dot-Com Bust...Weiss Ratings | SponsoredThe first casualty of the 2025 trade warThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | Sponsored2025 could be "worse than the dot-com bust", says man who predicted 2008 banking crisisWhat's coming next to the U.S. market could be worse than anything we've ever seen before – worse than the dot...Stansberry Research | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enanta Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enanta Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
